

1/24

Intranasal application of Transfersulin  
IDDM test person,  $\sim 0.8$  IU/kg




Fig. 1

2/24

Intranasal application of Transfersulin  
on a normoglycaemic test person, ~ 0.15 IU/kg (2x)





Fig. 2

3/24

Intranasal application of Transfersulin  
on a normoglycaemic test person, ~ 0.15 IU/kg (2x)

**Fig. 3a**

4/24

Intranasal application of Transfersulin  
in IDDM test person, ~0.4 IU/kg




Fig. 3b

5/24

Effects of nasally administered  
cytokines on specific immune response,  
1st boost + 7 d




Fig. 4

6/24




Fig. 5

7/24




Fig. 6

8/24

Intranasal administration: Tetanus toxoid (TT, impure )





Fig. 7a



9/24

Intranasal immunisation: Tetanus toxoid (TT impure)



Reciprocal antiserum dilution x 10<sup>2</sup>

Antigen dose in all the groups : 40 µg per mouse

Fig. 7b

■ SPC:NaCh (4.5:1)  
 ● Mixed micelles (SNa 1:1)  
 ▲ SPC:Cholesterol (1:1)

Intranasal immunisation: Tetanus toxoid (TT, impure)  
Effect of carrier size and deformability




Fig. 7c

11/24

Intranasal Immunization: Tetanus toxoid, (TT, *purified*)  
dose effect




Fig. 8a

# Intranasal immunisation: Tetanus toxoid (TT, purified), Effect of antigen dose




Fig. 8b

# Intranasal Immunization: Tetanus toxoid (TT, purified), dose effect




Fig. 8c

Noninvasive immunisation: Tetanus toxoid (TT, purified)  
effect of application route




Fig. 9a





Fig. 9b

# Antigen-specific Isotyping: Intranasal / Subcutaneous

40 µg Tetanus Toxoid (TT), ultrafiltered



Antiserum dilution Fig. 9c



17/24

# Intranasal immunisation: Tetanus toxoid (TT)

dose and route of administration effect




Fig. 10a

18/24

Intranasal immunisation: Tetanus toxoid (TT, purified) dose effect





Fig. 10b

Intranasal immunisation: Tetanus toxoid (TT, impure)  
effect of immunomodulators



Intranasal immunisation: Tetanus toxoid (TT, impure, 40 µg), effect of immunomodulators,




Fig. 11b

SPC:Tw-80 3.5:1

Intranasal immunisation: Tetanus toxoid (TT, purified)  
effect of immunopotentiators





Fig. 12

22/24  
Potentiation of nasal immune response to tetanus  
toxoid (TT) by bacterial adjuvant, cholera toxin (CT)



TfsT: SPC:Tw80(1:1)

TfsC: SPC:NaCholate(3.75:1) Time after challenge (hours)

CT dose: 2µg per dose




Fig. 13

# Adjuvant effect: of Heat Labile Toxin (LT) from E.coli




Fig. 14

**Bi-Valent Vaccines: Anti-Tetanus and -Cholera response**  
to the antigens administration in Transfersomes in the nose




Fig. 15